M. Marchand

发表

A limiting dilution assay for quantifying Leishmania major in tissues of infected mice

T. Boon, R. Titus, J. Louis, 1985, Parasite immunology.

The majority of autologous cytolytic T-lymphocyte clones derived from peripheral blood lymphocytes of a melanoma patient recognize an antigenic peptide derived from gene Pmel17/gp100.

H. Zarour, J. Renauld, P. Romero, 1996, The Journal of investigative dermatology.

Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis

C. Uyttenhove, T. Boon, J. Snick, 1980, The Journal of experimental medicine.

Human gene MAGE-1, which codes for a tumor-rejection antigen, is expressed by some breast tumors.

P. Chomez, F. Brasseur, T. Boon, 1992, International journal of cancer.

Trypanosoma cruzi variants with reduced virulence obtained by mutagenesis

T. Boon, M. Marchand, M. Marchand, 1984, Parasite immunology.

Increased frequency of immunogenic variants obtained by repeated mutagen treatment of mouse mastocytoma P815.

T. Boon, P. Caspar, M. Marchand, 1983, European journal of cancer & clinical oncology.

Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides.

F. Brasseur, M. R. Oliva, T. Boon, 1998, Tissue antigens.

Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. VI. Occasional escape from host rejection due to antigen‐loss secondary variants

C. Uyttenhove, T. Boon, M. Marchand, 1983, International journal of cancer.

Variants with reduced virulence derived from Leishmania major after mutagen treatment

T. Boon, R. Titus, J. Louis, 1987, Parasite immunology.

Perspectives for immunization of HLA-A1 patients carrying a malignant melanoma expressing gene MAGE-1.

P. Coulie, F. Brasseur, T. Boon, 1993, Dermatology.

Cutaneous leishmaniasis: relative role of T cell subsets.

T. Boon, R. Titus, J. Louis, 1988, Advances in Experimental Medicine and Biology.